The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The following report suggests that pressures on European cancer treatment are likely to grow significantly with 40% of specialist oncologists predicted to retire/leave over the next 5 years
https://www.rcr.ac.uk/media/hplj0uth/rcr-census_clinical-oncology-workforce-census_2022.pdf
'The need for novel oral cancer drugs, take at home and in the community, will only grow as hospital systems become more overloaded, and the numbers of specialist oncologists continues to decrease'
Must be some real opportunities here for PYC
Ant, thanks for your excellent contributions which are most interesting and welcome
PYC have been banging the drum for personalised medicine for many years. They should be well placed to take full advantage now that the industry has finally recognised its huge potential opportunities and benefits
DosemeRx have posted this which suggests they have strong growth ambitions and would be an excellent partner if PYC are able to strike a commercial deal with them
https://doseme-rx.com/news-media/article/doseme-expands-global-footprint-in-australia
On a recent IMC presentation JM mentioned that 'at the point when we mutually decide that we want to move to a commercial phase that will be quite quick because Doseme clients use the tool on a Cloud-based system and it doesn't require a complicated and lengthy roll-out'
I was a bit unsure when the company announced that it was initiating a company newsletter
However, I have been impressed by how much relevant news has been contained in the first few issues. It is a credit to the determined effort PYC are making to improve the profile of the company. Lets hope this continues in the near term with details regarding the Head of Modelling appointment, maybe an update on the G-CSF project, some important news on the Biostatistics initiative, contract announcements etc. Exciting times for those with a genuine interest
Dr Putcha was appointed as Head of Bio-statistics on 3rd October, 2023. Over six months later and we have heard nothing and he does not appear on the list of Team members on the company website
Maybe he is being kept back for the big Bio-statistics update promised sometime before 30th June ?
I have noted this before, but there is a similarity in parts of the wording used by Physiomics and Valirx. I feel it is not a coincidence. Here is the latest example :
PYC tweet 4th April 'Our latest news roundup .....' whilst Valirx tweet 9th April 'Welcome to the latest edition of our news roundups'
JM commented in the most recent IMC presentation that 'our financial and operational success is not dependent on what happens at Valirx'. I would take this to mean that there are no imminent plans for any closer ties between the two, which is good to know
Very early days I know, but the benchmark by which I will be judging Peter Sargent's performance as CEO is the company share price. Price on the trading day immediately before he was appointed (21st January) was 1.80. Price now 1.10
I like what I have seen and heard to date in his presentations and I am hoping that this now starts to feed through to the share price and we get back to at least the pre-appointment levels by financial year end. Some quality RNS releases are
what is now needed
Extremely disappointed that Angel Investor and NED Shalabh Kumar has not put his hand in his pocket and taken a decent chunk of shares by now Same for the rest of the Board of Directors who are happy to accept free options or take shares in a knock-down placing but show no enthusiasm for investing at full price like the rest of us lesser mortals
It would be an excellent way for the BOD to prove to the new Principal Consultant - Head of Modelling in no uncertain terms that they genuinely have big ambitions for growing not only sales but, more importantly, shareholder value
Interesting that DoseMeRx have reposted this PYC tweet :
'Check out this insightful article from our partner @DoseMeApp highlighting the vital role of #precisionmedicine in #oncology and beyond'
I feel that a commercial deal between the two companies is likely if the G-CSF trials go well
I would say it's a buy, but not particularly fussed
If they are giving 1.29 for 500k for a larger sell then could suggest some behind-the-scenes demand. Maybe Peter Sargent after a few million (joke)
Current price range is 1.23 -1.33 for modest amounts
In the recent presentation, JM touched on the development of the PYC precision dosing tool to predict GCSF levels (currently subject to Innovate-funded trials involving Beyond Blood/Blackpool Hospital) and also mentioned that they were in discussions with Dosemerx to see whether there may be 'some way to work with them to gather more data'
I get a feeling that both Dosemerx and PYC see good potential here
PYC now showing 'X' link to Dosemerx Precision Dosing article with this additional comment :-
'we're proud to be working alongside @DoseMeApp in advancing this field, leveraging mathematical modelling and clinical decision support software to tailor drug dosages and improve treatment outcomes for cancer patients'
I feel that we should get a decent update on progress with the Dosemerx partnership over the next few months
Never quite understood why market makers are prone to exaggerate the true bid-offer range. Clearly the current range here is around 1.21-1.29 and not 1.20-1.40 , as shown
Are they trying to dissuade buyers for some reason or is it just laziness on their part. Surely they are depressing interest and potentially losing some commission as a result